

Abridged
PROGRAM

www.isber.org



Visit Azenta Life Sciences in the Exhibit Hall





PARTICIPATE FROM YOUR DESKTOP OR MOBILE DEVICE

- **1.** Download "Pheedloop Go" from your devices app store
- 2. Login using your email address
- **3.** Use "Forgot Password" to set a new password
- 4. Search for "ISBER2023Annual"





ISOET JUNE 6-7 JUNE 6-7 Virtual Annual Meeting

DOWNLOAD THE ISBER 2023 MOBILE APP!



Vision

To be the leading network in the global biobanking and biorepository community.

Mission

ISBER advances the expertise and quality of biorepositories and biobanking science worldwide.

INTERNATIONAL SOCIETY FOR BIOLOGICAL AND ENVIRONMENTAL REPOSITORIES

International Society for Biological and Environmental Repositories
1618 Station Street, Vancouver, BC, V6A1B6 Canada | T 604.484.5693 | F 604.874.4378



DIAMOND



GOLD





SILVER



FARRAR



BRONZE





















EXHIBITOR LISTING

Company	Company
A2LA	GenVault Biorepository
AltemisLab	Greiner Bio-One
ASKION GmbH	Haier Biomedical
ATP Bio	Hamilton Storage
Autoscribe Informatics Inc.	IC Biomedical, LLC
Avantor	iSpecimen
Azenta Life Sciences	Kaye – a Subsidiary of Amphenol Advanced Sensors
B Medical Systems	LabVantage Solutions, Inc.
BioFortis, a Q2 Solutions Company	Liconic
BioLife Solutions	LVL technologies GmbH Co. KG
Bluechiip Limited	Modul-Bio
Bruker	MVE Biological Solutions
BSI Systems	Olink Proteomics
celltrio	OpenSpecimen Biobanking LIMS
CloudLIMS.com	OriginCell Instruments
College of American Pathologists	phasetwo
Cryoport Systems	PHC Corporation of North America
Cryotherm	StageBio
DiData-ISENET	Rees Scientific
Ellab Inc.	Thermo Fisher Scientific
FARRAR / Trane Technologies	TubeWriter
Freezerworks	Zymo Research
iSpecimen	



TABLE OF CONTENTS

ISBER Sponsors	5
Exhibitors	
Message from the ISBER President	8
Message from the Scientific Program Task Force Co-Chairs	C
ISBER Board of Directors and Community of Practice Chairs	11
ISBER Award Recipients	12
General Conference Information	13
Live Session Program	16
On Demand Program	18
Poster Sessions	24



MESSAGE FROM THE ISBER PRESIDENT

Dear colleagues and friends,

On behalf of the International Society for Biological and Environmental Repositories (ISBER) Board of Directors, I extend you a warm welcome to the 2023 ISBER Annual Meeting, in person on 3-6 May 2023 in Seattle, Washington, USA, and virtually on 6-7 June 2023.

Under the leadership of our Scientific Program Co-Chairs, Drs. Anusha Hettiaratchi (Australia), Birendra Kumar Yadav (India), and Dayong Gao (USA), and supported by a creative and hard-working Program Planning Task Force, this year's theme is "Come as you are: Building Biobanking Bridges". For the engineers among us, building bridges might be a familiar way of life. The events of recent years have necessitated many more bridge builders to fill the growing and evolving needs. These bridges would now create both physical and virtual communities and communications networks, joint research or clinical entities, and more. The concept of neighbor has evolved and expanded as ease of access to entities is no longer solely dependent on physical proximity.

During your time at the meeting, we encourage you to build and/or cross a few bridges of your own...to stronger and broader networks and knowledge. With great thanks to our invited speakers, guests, workshop presenters, and roundtable leaders, there are many opportunities on the ISBER program—without you, there can be no bridge building. These are just a few possibilities: join a session on novel technology and methods; understand some of the updates coming to the ISBER *Best Practices* 5th Edition; learn about how biobanks are working with Pharma; hear the latest on biobanking research; participate in an education workshop on specimen sharing or be a part of a roundtable on the Biobank Assessment Tool (BAT), or data management.

Thank you to our sponsors, who have continually supported both ISBER and biobanking. I am delighted to say that we have a full exhibit hall with opportunities for learning that complement our scientific program. I encourage you to speak with our vendors and participate in corporate sessions. Visit the exhibit hall to talk to our sponsors and vendors, see the latest technology and equipment, and learn about many of the tools and resources available to biobankers.

They provide a gateway to many of the advancements in biobanking.

Thank you to our ISBER Head Office Staff, who have supported us throughout the year on all aspects of this endeavor. In particular, thank you to Samantha Wale for navigating us so adeptly through the intricacies of developing a hybrid conference.

Last and certainly not least, thank you to our members and visitors to this meeting. Without you, none of this is possible. I hope that you will use this meeting to build your own bridges.

Sincerely

Clare M. Allocca

ISBER President 2022-2023 National Institute of Standards & Technology (NIST)

Clare W. Allocia

IISA



MESSAGE FROM THE SCIENTIFIC PROGRAM TASK FORCE CO-CHAIRS

Dear colleagues and friends,

On behalf of the International Society for Biological and Environmental Repositories (ISBER) Program Planning Task Force of the 2023 Annual Meeting and Exhibits, we welcome you to the meeting!.

Partially channelling one of Seattle's best known and loved musical exports, the theme for this year's conference "Come as you are: Building Biobanking Bridges" has been realised by a Program Planning Task Force which has itself bridged time zones between Australia, Austria, Canada, Côte d'Ivoire, Egypt, Germany, India, Nigeria, Poland and the United States. Biobanking has always existed as a conduit between industry, academia, technology, research, policy, regulation, and ethics, while operating across varying economic, religious, cultural and social spectrums; this meeting aims to showcase not just the breadth of biobanking activities current and emerging, but common solutions to road-blocks, to bring together ideas, industries, technologies and of course the biobanking professionals themselves.

The symposia this year offer a variety of topics that explore the meeting theme, include invited speakers from around the globe, and encompass a wide variety of professions. Symposium 1 explores the different measurable impacts, health and economic for example, bridged by biobanks, and explores their importance including those in LMIC. Symposium 1 will also feature our keynote speaker Dr. Jairam Lingappa from the International Clinical Research Centre. Symposium 2A examines boundaries such as diversity, equity and inclusion to overcome in biobanking and Symposium 2B bridges biobanking science with practice. Symposium 3A focuses on the collaboration between biobanks and pharma, while Symposium 3B has a focus on biobanking and data. The last, Symposium 4 aptly titled 'as you are, as you were, as you want to be', looks at evidence based biobanking research ('as you are' and 'as you were') and how biobanking can promote more sustainable biobanking investment ('as you

want to be').

This year's meeting will feature opportunities to learn and discuss at round table discussions, contributed paper sessions, workshops and a session on ISBER *Best Practices* 5th Edition. There are opportunities to engage with our vendors and sponsors not just in the exhibit hall but within the meeting program during the corporate Isessions and the innovative technologies session.

We were pleased to receive 165 abstract submissions along with 27 late breaking submissions. A selection of these were chosen for the contributed paper sessions and delegates are able to view the remaining accepted abstracts as poster presentations. We received workshop proposals spanning a range of topics, those selected including biospecimen requests, best practice, funding, biospecimen sharing, effective biospecimen utilization and bridging biobanks with next generation technologies. Thank you to all our Program Planning Task Force and Workshop Review Task Force members who took the time to carefully review and score the abstract and workshop session submissions.

To our corporate sponsors thank you for your support of ISBER's annual meeting. From all the co-chairs, thank you to the ISBER Head Office staff for their guidance and support throughout this year as we put together our program. To all our meeting delegates we hope you are able to use this year's conference to its full potential to learn, network, and bridge new biobanking frontiers.

Dayong Gao University of Washington,

University of Washington, Seattle, USA **Anusha Hettiaratchi**

University of New South Wales, Sydney, Australia **Birendra Kumar Yadav**

National Liver Disease Biobank, New Delhi, India

B Reliable. B Dependable. B Medical.



When it comes to cold chain solutions, reliability is key. B Medical Systems has proven time and time again that our technology is the standard above the standard.

Which is why our cold storage solutions are meticulously engineered for consistent performance with state-of-the-art insulation and user-focused design so our cold chain products maintain consistent temperature in the most demanding environment. So, vaccines, blood samples and bio specimens remain safe. You can count on that, every time.

For ordering information, call toll-free **888-456-7099**.

Or view our full range of ultra-low temperature freezers at **bmedicalsystems.com**.







ISBER BOARD OF DIRECTORS AND COMMITTEE CHAIRS

ISBER BOARD MEMBERS

Alison Parry-Jones, PhD, MA, MRSC

PRESIDENT-OF-THE-BOARD
May 2023 – May 2024
Wales Cancer Bank - Cardiff University
South Glamorgan, United Kingdom

Clare M. Allocca, MS, PMP

PAST PRESIDENT-OF-THE-BOARD
May 2023 – May 2024
National Institute of Standards & Technology
Maryland, United States

Dayong Gao, PhD, BSc

PRESIDENT ELECT-OF-THE-BOARD
May 2023 – May 2024
University of Washington
Washington, United States

Cathy Seiler, PhD

TREASURER
May 2023 – May 2026
AstraZeneca
Massachusetts, United States

Rebecca Pugh, MS

SECRETARY
May 2023 – May 2026
National Institute of Standards and
Technology
South Carolina, United States

Monique Albert, MS, PMP

SECRETARY
May 2020 – May 2023
Centre for Biodiversity Genomics,
University of Guelph
Ontario, Canada

William Schleif, PhD

DIRECTOR-AT-LARGE - Americas May 2023 – May 2026 Johns Hopkins All Children's Pediatric Biorepository Florida, United States

Xun Xu, PhD

DIRECTOR-AT-LARGE - China May 2021 – May 2024 China National GeneBank Guangdong, China

Engela Conradie, PhD, Pr.Sci.Nat

DIRECTOR-AT-LARGE - Europe, Middle East, Africa May 2022 – May 2025 Centre for Human Metabolics Potchefstroom, South Africa

Wayne Ng, PhD

DIRECTOR-AT-LARGE - Indo-Pacific Rim May 2023 – May 2027 Victorian Cancer Biobank Melbourne, Australia

COMMUNITY OF PRACTICE CHAIRS

Education and Training

Chair: Tamsin Tarling University of British Columbia British Columbia, Canada

Science Policy

Chair: Helen Morrin Cancer Society Tissue Bank, University of Otago Christchurch, New Zealand

Vice-Chair: Rita Lawlor

ARC-NET Centre for Applied Research on Cancer Verona, Italy

Standards

Chair: Annemieke De Wilde Belgian Cancer Registry/BBMRI.be Brussels, Belgium

Vice-Chair: Samantha Higgins Victorian Cancer Biobank Melbourne, Australia



ISBER AWARDS

ISBER Award for Outstanding Achievement in Biobanking

The ISBER Award for Outstanding Achievement in Biobanking, sponsored by ABS Bio, is designed to recognize individuals who have made outstanding contributions to the field of biobanking. The award can be given for a single outstanding achievement or a lifetime body of outstanding work in the field.

Peter Watson,

BC Cancer Agency, Canada

Sponsored by:



ISBER Distinguished Leadership and Service Award

The ISBER Distinguished Leadership and Service Award is designed to honor ISBER members who have demonstrated exceptional leadership to further the mission and goals of the society and/or significant, long-standing contributions to the society.

Monique Albert

Centre for Biodiveristy Genomics, University of Guelph, Canada

Sponsored by:



ISBER Special Services Awards

The ISBER Special Service Awards recognize individuals who have made exceptional contributions towards the goals of the Society through the performance of a special service or act on behalf of the organization.

Annemieke De Wilde,

Belgian Cancer Registry/BBMRI.be, Belgium

Rita Lawlor,

ARC - NET Centre for Applied Research on Cancer, Italy

Helen Morrin,

University of Otago, New Zealand

Tamsin Tarling,

University of British Columbia, Canada

Emma Snapes,

BioConsulting Ireland



GENERAL CONFERENCE INFORMATION

Virtual Meeting Platform

Access the virtual meeting platform:

- Desktop: https://pheedloop.com/ISBER2023
- Mobile App: Download "Pheedloop Go" from your app store

Username: your email address* Password: use "forgot password" to set your password

*be sure to login using the same email address you used to register for the meeting.



Exhibits:

The exhibit hall is available for you to peruse at your leisure.

Exhibitors will be available within their booths to answer your questions at the following time:

Tuesday, June 6:

- NA Pacific Time: 7:45am 8:45am and 5:00pm 6:00pm
- NA Eastern Time: 10:45am 11:45am and 8:00pm 9:00pm
- Central European Time: 4:45pm 5:45pm
- China Standard Time: 10:45pm 11:45pm

Wednesday, June 7:

China Standard Time: 8:00am – 9:00am
Australian Eastern Time: 10:00am – 11:00am

Registration Rates (Prices in USD)

	Regular Rate	On-Site Rate (After June 2)
ISBER Member	\$515	\$615
Non-ISBER Member	\$640	\$740
Technician/Student Member	\$330	\$380
Technician/Student Non-Member	\$430	\$480

Certificates of Attendance

All attendees will receive a certificate of attendance electronically upon completing the post-conference delegate evaluation. This will be distributed via email on June 8, NA Pacific Time.

Poster Presentation Information:

All abstract posters are available for you to view within the mobile app – this includes all posters that were presented in Seattle, USA, and those that are being presented virtually only.



Freezerworks Sample Management Software

Reward your laboratory with the configurable and affordable LIMS solution it deserves.





CLICKConfigure Quickly, Go Live Fast



PROTECT
Share Data
Securely



OPTIMIZEFewer Steps,
Better Data



COMPLYOur Audit Trail's
Got Your Back

CONFIGURABLE SUCCESS

With our configurable toolset, your team of sample management heroes will reach milestones faster. Improving the efficiency in your lab and reducing the workload for your users has never been more obtainable.

ACCURATE LABELING

Freezerworks has you covered if you need precise tracking of your cryogenic inventory, slides, vials, and more. Upgrade your labeling capabilities with Freezerworks to create labels with inventory data, barcode symbology, and branding.



COMPLETE AUDIT TRAIL

Our fully automated audit trail helps you meet 21 CFR part 11 requirements. Stop wasting your time investigating who changed what data and let Freezerworks track every addition and update.

ACCOMPLISH MORE

- Take granular control of privileges granted to users and groups
- Streamlined sample lineage tracking
- Protect sensitive patient data from unauthorized viewers
- Organize clinical trial information
- Secure access to sample management tools from a web browser
- A support team ready to ensure your sample management success



©2023 Dataworks Development, Inc.

HAMILT®N





Hamilton BiOS®

Scalable to allow for the secure storage of up to 22 million samples





SAM HD

Small but powerful storage of up to 85,000 samples



Hamilton's line of automated -80°C storage systems and benchtop devices help to increase efficiency while maintaining sample integrity.







LabElite® Handheld DeCapper

Repeatable screw cap tube decapping/capping in the palm of your hand







LabElite® DeFroster

Fast and effortless removal of frost from tube racks







LIVE SESSION PROGRAM

TUESDAY, JUNE 6 (WESTERN HEMISPHERE)
TUESDAY, JUNE 6/WEDNESDAY, JUNE 7 (EASTERN HEMISPHERE)

TUESDAY, JUNE 6/ WEDNESDA	AY, JUNE / (EASTERN HEMISPHERE)			
6:00am – 6:15am NA Pacific 9:00am – 9:15am NA Eastern 3:00pm – 3:15pm Central Europe 9:00pm – 9:15pm China Standard 11:00pm – 11:15pm Australian Eastern	Welcome Remarks Alison Parry Jones, ISBER President 2023-2024 Anusha Hettiaratchi, Dayong Gao, Birendra Kumar Yadav, 2023 Program Planning Task Force Co-Chairs			
	ROUNDTABLE DISCUSSION			
	Using the BAT to hit a Homerun for your Biobank Annemieke De Wilde, BBMRI.be, Belgium			
(CONCURRENT)	Network to benefit the Biobanking Community: Create or Enhance an ISBER Community of Practice, Working Group or Special Interest Group Clare Allocca, National Institute of Standards and Technology, USA			
6:30am – 7:30am NA Pacific 9:30am – 10:30am NA Eastern 3:30pm – 4:30pm Central Europe 9:30pm – 10:30pm China Standard 11:30pm – 12:30am Australian Eastern	Children's Health, Research, and Biobanking – How Do We Juggle it All with Less? Billy Schleif, Johns Hopkins All Children's Pediatric Biorepository, USA, Rania Labib, Boston Children's Hospital, USA, Daniel Catchpoole, The Children's Hospital at Westmead, Australia			
11.50pm – 12.50am Australian Eastern	The Considerations and Barriers to Implementation of 5 th Ed. Best Practices: Real World Discussion of Information Management BPs Marianne Henderson, National Cancer Institute, USA			
	The ISBER/ASCPBOC Qualification in Biorepository Science (QBRS) Exam Brent Schacter, CancerCare Manitoba/University of Manitoba, Canada			
7:30am – 8:30am NA Pacific 10:30am – 11:30am NA Eastern 4:30pm – 5:30pm Central Europe 10:30pm – 11:30pm China Standard (June 7) 12:30am – 1:30am Australian Eastern	Visit with Exhibitors The exhibitors will be available within their booths during this time to interact and ask questions.			
(CONCURRENT)	Educational Workshop: Navigating the Needs of Our Researchers; Working Through Demanding Biospecimen Requests			
8:30am – 10:30am NA Pacific 11:30am – 1:30pm NA Eastern	Katy McCortney, Nervous System Tumor Bank; Northwestern University, USA			
5:30pm – 7:30pm Central Europe 11:30pm – 1:30am China Standard	Educational Workshop: From Human Microbiome to Strain Collections: Technical, Molecular and Regulatory Aspects			
(June 7) 1:30am – 3:30am Australian Eastern	Fay Betsou, Dominique Clermont, Raquel Hurtado-Ortiz, Federica Palma, Institut Pasteur, France			



TUESDAY, JUNE 6 (WESTERN HEMISPHERE) TUESDAY, JUNE 6/WEDNESDAY, JUNE 7 (EASTERN HEMISPHERE)

(CONCURRENT)

3:00pm - 4:00pm NA Pacific

6:00pm - 7:00pm NA Eastern

(June 7) 12:00am – 1:00am Central Europe

(June 7) 6:00am – 7:00am China Standard

(June 7) 8:00am – 9:00am Australian Eastern

4:00pm - 5:00pm NA Pacific

7:00pm - 8:00pm NA Eastern

(June 7) 1:00am – 2:00am Central Europe

(June 7) 7:00am – 8:00am China Standard

(June 7) 9:00am – 10:00am Australian Eastern

ROUNDTABLE DISCUSSION

Understanding the New NIH Data Management and Sharing Requirements

James McNally, University of Michigan, USA

Biobanking 101 Workshop debrief

Debra Leiolani Garcia, Independent Consultant, USA, **Marianne Henderson**, National Cancer Institute, USA, **Diane McGarvey**, CHTN Eastern Division, University of Pennsylvania, USA

Universal Consent for Biobanking

Sara Bowen, Barrow Neurological Institute, USA

Visit with Exhibitors

The exhibitors will be available within their booths during this time to interact and ask questions.

WEDNESDAY, JUNE 7 (WESTERN HEMISPHERE) THURSDAY, JUNE 8 (EASTERN HEMISPHERE)

10:30am – 11:00am NA Pacific

1:30pm - 2:00pm NA Eastern

7:30pm – 8:00pm Central Europe

(June 8) 1:30am – 2:00am China Standard

(June 8) 3:30am – 4:00am Australian Eastern

Live Q&A with the Keynote Speaker

Jairam Lingappa, University of Washington, USA

(CONCURRENT)

3:00pm – 5:00pm NA Pacific

6:00pm - 8:00pm NA Eastern

(June 8) 12:00am – 2:00am Central Europe

(June 8) 6:00am – 8:00am China Standard

(June 8) 8:00am – 10:00am Australian Eastern

Educational Workshop: Sustaining Best Practices of Biobanks During Pandemics

Karen Meagher, Mayo Clinic, USA, Subhashini Chandrasekharan, National Institutes of Health, USA, Aaron Goldenberg, Case Reserve University, USA

Educational Workshop: Building Bridges: Towards An International Framework for Specimen Sharing

Marianna Bledsoe, Biopreservation and Biobanking, USA, Mark Barnes, Ropes & Gray, USA, Annette Schmid, Takeda Pharmaceutical Company Limited, USA, Rita Lawlor, ARC-NET Centre for Applied Research on Cancer, Italy, Helen Morrin, University of Otago, New Zealand



ON DEMAND SESSIONS

Symposia

SYMPOSIUM 1: MEASURING BIOBANK IMPACT - SCIENTIFIC RESEARCH, HEALTH, AND GLOBAL ECONOMY

Chairs: Wayne Ng, Anusha Hettiaratchi, Birendra Kumar Yadav and Dayong Gao

It is generally agreed that biobanks make significant impacts on the progression of medical research, and increasingly to other areas, such as agriculture and rare species conservation. However, it is often challenging to identify and quantify these impacts due to diverse biobank functionalities and complex governance. Defining and measuring the impact of biobanking is critical for business value proposition and sustainability. Such measurements can provide biobank stakeholders (e.g. funders, policy makers and the broader population) with the ability to better assess biobank value, and allow biobanks to develop their strategic direction.

This symposium explores the different types of measurable impacts (e.g. health and economy) that can be created by biobanks, and considers the importance of these impacts for research and innovation sectors, funders and governments. Consideration will be given to the types of impacts generated and their importance for emerging biobanks (e.g. biobanks in lower- and middle-income countries).

ISBER Welcome Address

Clare Allocca, ISBER President-of-the-Board 2022-2023

Scientific Program Co-Chair Welcome Remarks

Dayong Gao, Anusha Hettiaratchi, Birendra Kumar Yadav, Scientific Program Task Force Co-Chairs

KEYNOTE – The International Clinical Research Center (ICRC) Specimen Repository: A History of Contributing to Challenging Public Health and Translation Research

Jairam Lingappa, University of Washington, USA

Game on Biobanks, Time to Step Up

Eng Chon Boon, National University Health System, Singapore

Operationalizing Precision Medicine through Industrialization of Human BioAsset and Digital Asset Management

Brenda Yanak, Clinical Transformation Partners LLC, USA

Quantifying the Impact of the Victorian Cancer Biobank through Gains on Wellbeing

Zanfina Ademi, Monash University, Faculty of Pharmacy and Pharmaceutical Sciences, Australia

The Emerging Biobanks in Africa for Genomic Studies

Segun Fatumo, London School of Hygiene and Tropical Medicine, United Kingdom

Banking on Impact - Building a Bridge Between Your Stakeholders and Your Biobank

Debra Jaramilla, Cornell Veterinary Biobank, USA



SYMPOSIUM 2A: PRIORITIZING DIVERSITY, EQUITY, AND INCLUSION IN BIOBANKING

Community engagement for biobanking should not be an afterthought, but instead should be prioritized and considered before the study plan is finalized. Thought and planning in defining the "communities" is needed, and study staff need to make an extra effort to include minority participants and other typically underserved participants. Participants in biobanking studies want to be seen and heard and more often, want to "get something back" from their participation. This may be individual results, or general study updates. Community engagement is a sign of respect and garners trust with potential participants, without whom we could not do research.

A Participant Perspective on Biobanking

Janet Freeman-Daily, The ROS1ders, USA

African American Representation in Biobanking and Tumor Sequencing Studies: Experience at Washington University in St Louis

Graham Colditz, Washington University School of Medicine, USA

Community Engagement in Biobanking: Public Perspectives, Challenges and Need of the Hour

Bushra Rakha, Pir Mehr Ali Shah Arid, Agriculture University Rawalpindi, Pakistan

Necessary, but Not Sufficient: The Limitations of Inclusion as an End Goal for Addressing Equity in Biobanking

Aaron Goldenberg, Case Western University, USA

Diversity, Equity, and Access: Achieving Equity in Research Participation

Nadine Barrett, Center for Equity in Research; Duke Clinical and Translational Science Institute, USA

SYMPOSIUM 2B: BRIDGING SCIENCE AND PRACTICE - NOVEL TECHNOLOGY AND METHODS FOR BIOBANKING

Over the past 30 years, biobanking has become indispensable for promoting and generating great advances and breakthroughs in biological research spanning human disease, conservation efforts, ecology, microbiology and zoology. Notable highlights include advances in clinical diagnosis and treatments such as gene/cellular therapy and stem cell/tissue transplantation as well as re-population of critically endangered species and botanical crops. Biobanks are critical bio-resource suppliers, making measurable impacts on the research and development in regenerative medicine, tissue engineering, personalized medicine, new vaccine or drug development, disease screening, in vitro fertilization, bio-technology development, and conservation of endangered species. This symposium focuses on the research and development of pioneering technology and methods for use in biobanking practice to ensure the biospecimen quality, security, and useability. Key areas of focus will range from optimal techniques for biospecimen collection in challenging environments such as remote locations or emergency settings to the novel technology, instruments, and tools for biospecimen cryopreservation based on solid scientific foundations and emerging data.

Biobanking as a Tool for Integrative Conservation: One Piece of the Puzzle

Rose Upton, University of Newcastle, Australia

Fundamental and Applied Cryobiology Research for Biopreservation and Biobanking: Translating Science into Practice

Zhiquan Shu, University of Washington, USA

Biobanking in Rough Waters

Amanda Moors, National Institute of Standards and Technology, USA

Advances in the Low Temperature Stabilization of Cells and Tissues

Jason Acker, University of Alberta, Canada

Challenges and Opportunities in Neurobiobanking in Resource-Limited Settings: Experience from West Africa

Rufus Akinyemi, University of Ibadan, Nigeria

Cryopreserved Innate Cell Product Enables Off-the-Shelf Allogeneic Cell Therapy Development

Yana Wang, Takeda, USA



Innovative Technologies

An Analytical Method to Determine Quality of Fixation Using Vibrational Spectroscopy and Machine Learning David Chafin, Roche Diagnostics International AG, USA

Electromagnetic Heating Technology for the Fast and Uniform Rewarming of Cryopreserved Large Volume Samples Ziyuan Wang, University of Washington, USA

OMICS-QC: Integrative Model of Quality Control of Plasma and Serum Samples for Multi-Omics Approach Anna Michalska-Falkowska, Medical University of Bialystok, Poland

Spa Biobank: A New Type of Biobank

Judita Kinkorová, University Hospital Pilsen, Czech Republic

Al and the Metaverse as the Drivers of Change for Biorepositories

Jean Fallacara, inTEST Thermal Solutions, USA

Bridging the Gap Between Biobanks and Industry

Maria Menikou, Scientist.com, United Kingdom

Biobanking as a Foundational Component of NIH Research: Sampled Provides a Critical Resource for Research into the Genetics and Epigenetics of Substance Abuse in Humans through its National Institute of Drug Abuse (NIDA) Centers Michael Sheldon, Sampled, USA

Two-for-One: Optimizing Histologic Quality Control of Fresh Tissue Disbursement and Simultaneously Banking for Future Use

Elizabeth Howington, Duke University School of Medicine, USA

SYMPOSIUM 3A: JOINT ACTIONS OF BIOBANKS AND PHARMA FOR A BETTER FUTURE

Knowledge about biobanking in the pharmaceutical sector and understanding of principles of collaboration between academia and pharma is limited. This session intends to familiarize academics and public sector biobankers with requirements, opportunities, and challenges of the private-public partnership. This includes informed consent, intellectual property rights, and obstacles in international biobanking. Although academia and pharma share the same biobanking aims, there are some major discrepancies in both sectors which will be highlighted to help understand challenges the pharmaceutical sector is facing.

Attendees will hear about biobanking standards and principles that the industry follows and in turn understand requirements of biobank partners in order to facilitate effective, future collaboration with pharmaceutical companies.

Industry-Academia Collaboration - It Can work!

Alison Parry-Jones, Wales Cancer Biobank, United Kingdom

The Key Consent Considerations for Industry

Razan Humeida, AstraZeneca, United Kingdom

Intellectual Property: Can We Share It or Not?

Kerry Powers, Roche Diagnostic Solutions, USA

Importance and Opportunity of Translational Study Leveraging Resource from Biobank and Hospital in China Andy Wang, Yunxin Chen, Bayer Healthcare, China



SYMPOSIUM 3B: DATA AND BIOSPECIMENS - GREATER THAN THE SUM OF ITS PARTS

The data that accompanies biospecimens is equally important as the material in the vial. In fact, only the data may be shared with researchers. But it can't be just data; in order to bring value, the data must be relevant, complete, accurate and reliable. Collecting, managing, storing, and sharing high quality data requires resources, careful planning, and regular attention and review. In biobanking of human samples, participant privacy and confidentiality must be protected, while also making the data as useful and available as possible.

Connecting Specimen Records and Data Accessibility in the United States Department of Agriculture – Agricultural Research Service (USDA-ARS) Culture Collection

Kirk Broders, USDA ARS, USA

Integration of Information in the Brain Bank

Andres Villegas-Lanau, Neurobanco - Grupo de Neurociencias de Antioquia - Universidad de Antioquia, Colombia

Data Management for NCI's Cancer Moonshot Biobank - A Case Study

Anita Mohandas, Frederick National Laboratory for Cancer Research (FNLCR), USA, Veena Gopalakrishnan, National Institutes of Health – National Cancer Institute (NIH-NCI), USA

Large Scale Data and Data Analytics in Biobanking: Mapping Issues to Achieve Success

Gabrielle Samuel, King's College London / University of Oxford, United Kingdom

SYMPOSIUM 4: BIOBANKING RESEARCH - "AS YOU ARE, AS YOU WERE, AS I WANT YOU TO BE"

Chairs: Lalita Wadhwa, Krishnan Ramanujan

Biobanking research provides evidence about how biobanks support research and innovation in different real-world settings. Evidence from biobanking research ("as you are, as you were") could promote more sustainable biobanking investments that also deliver better research and other societal benefits ("as I want you to be"). The biobanking research symposium will showcase the current state of international biobanking research through invited presentations from biobanking research experts. The symposium will also feature presentations selected from submitted abstracts, with a focus on showcasing biobanking research undertaken by early career researchers.

The Rise and Fall of a Research Infrastructure – How a Promising Harmonisation Endeavour for Biobanking in Sweden Would Fail

Anthony Larsson, Stockholm Chamber of Commerce, Sweden

Towards What? Addressing Neglected Issues and Concerns in Contemporary Biobanking for Biomedical Research: A Social Sciences Approach

Violeta Argudo-Portal, University of Barcelona, Spain

When the Decision to Close a Repository is Reversed: The Ontario Tumour Bank Experience

Ilinca Lungu, Ontario Institute for Cancer Research, Canada



SYMPOSIUM 5: RISING STARS - NEXT GENERATION OF BIOBANKERS

The Rising Stars session was created to reach out globally to the next generation of biobankers to get a better understanding of their needs. The goal is to highlight the successful work of new up and coming biobankers to share their acheivements and challenges and to encourage them in their progress. This year, we will hear about biobanking in Vietnam, Mali, and Armenia. Furthermore, we will honor the work of Dr. Sameera Ezzat who passed away earlier this year, showcasing the work she had done in promoting her biobank.

Sameera Ezzat: A Rising Star that Vanished

Ahmed Samir Abdelhafiz, National Cancer Institute, Cairo University, Egypt

Tissue Bank in Vietnam: Characteristics and Development Opportunities

Duong Cong Nguyen, Viet Duc Hospital, Vietnam

Project to Establish Human Biobank Center in Mali: Opportunity, Strategy and Perspectives

Saidou Balam, University of Science, and Technology of Bamako (USTTB), Mali

ARICE: Twinning for the Armenian Research Infrastructure on Cancer Research

Karine Sargsyan, Cedars-Sinai Medical Center, USA



Corporate Symposia

Corporate Workshop 1: Leveraging Freezerworks Information Management Software to Achieve Compliance

Freezerworks
Sample Management Software

Mandy Riffel, Cheryl Michels, Freezerworks, USA

Corporate Workshop 2: Alternative Storage and Shipping Options for Cryopreservation Kevin Gilliland, MVE Biological Solutions, USA



Corporate Workshop 3: Empowering Genomics and Biomarker Discovery with Proteomics

Aparna Vasanthakumar, AbbVie GenomeResearch Center, USA, Andrea O'Hara, Azenta Life Sciences, USA, Cindy Lawley, Olink Proteomics, Inc., USA



Corporate Workshop 4: Flexibility in Freezing and Storage Applications to Safeguard Equipment Performance and Ensure Sample Integrity

Sylvain Riendeau, FARRAR / Trane Technologies, USA



Corporate Workshop 5: OpenSpecimen - Highly Configurable Biobanking LIMS

Srikanth Adiga, Poornima Govindrao, OpenSpecimen, India



Corporate Workshop 6: Emerging Technological Changes and Challenges to Ultra-Low Freezer Storage

Joe Laporte, Hans Brok, Hadar Aharoni, PHC Corporation of North America, USA



Corporate Workshop 7: Best Practices to Successfully Scale Your Biobank

Amy Armstrong, Wilfredo Marin, Tom LaSota, Thermo Fisher Scientific, USA



Corporate Workshop 8: Addressing Challenges in Logistics: How to Keep Sample Integrity on the Right Path

Chair: Vanessa Tumilasci, Azenta Life Sciences







Contributed Paper Session

Accelerating Translational Research by Enabling Access to Specimens and Datasets

Snehal Joshi, Fred Hutchinson Cancer Research Center, USA

Power of Consortium Shared Resources when External Threats Occur

Susan Hume, Victorian Cancer Biobank Consortium; Eastern Health, Australia

A New Tool to Match Organ, Tissue and Eye Post-Mortem Donors to Research Project Criteria

Kaitlyn Kunkle, Advancing Sight Network, USA

Determining Pre-Analytical Variables and Molecular Determinants to Ensure High Quality of Luxor Biobank

Nashwa Kordy, Shefa Al Orman Hospital, Egypt

Biobanking During War: Experience of Audubon Bioscience

Alexandra Giardina, Audubon Bioscience, USA

Survey of Adolescents Regarding Their Opinion of Research and Vaccination During the COVID-19 Pandemic

Qudrat Aujla, BC Children's Hospital, Canada

MIRRI-ERIC: A Pan-European Research Infrastructure for Making Microbial Science and Innovation Happen

Raquel Hurtado-Ortiz, MIRRI-ERIC, France

Developing Genomic and Biomaterials Resources for Establishing Non-human Primate Models of Human Disease

Eric Vallender, The University of Mississippi Medical Center; Tulane National Primate Research Center, USA

Al in Medicine Based on Biobank Data - New Opportunities and (Not) Known Risks

Karine Sargsyan, Cedars-Sinai Medical Center, USA

Challenges and Opportunities for mBRCs in the Era of Regulated Access Policies

Raquel Hurtado-Ortiz, Institut Pasteur, France

How Can and Should Biobanking Governance Structures Respond to (Inter)national Political Contexts?

Rachel Thompson, University of Oxford, United Kingdom

Costs and Publication Outputs of an Academic Cancer Biobank Cohort

Amanda Rush, The University of Sydney Faculty of Medicine and Health, Australia

The Qualification in Biorepository Science (QBRS) Examination: Progress Report on its Global Reach

Brent Schacter, CancerCare Manitoba; University of Manitoba, Canada

Tissue Microarrays: Turning Hidden Resources into Research Gems

Daniel Catchpoole, The Children's Hospital at Westmead, Australia

Genomic Taxonomy of Bacterial Strains in a Microbial Biorepository: The Instance of the Collection of Institut Pasteur (CIP)

Martin Boutroux, Institut Pasteur, France

Reassessing Historical Collections: Finding Novel Uses for Archived Specimens

Debra Ellisor, National Institute of Standards and Technology, USA

Surveying the Biobanking Landscape

Alison Parry-Jones, Wales Cancer Biobank, Cardiff University, United Kingdom

Evolution of Risk Management in Qatar Biobank (QBB)

Wilma Lobo, Qatar Foundation, Qatar



POSTER SESSIONS

ID	Title	Presenter	Country
PA-01	Design and Implementation of Nasopharyngeal Specimen Storage in Straws during the Covid 19 Pandemic in Ivory Coast	Rita Bouagnon	Côte d'Ivoire
PA-02	Conducting an Internal Audit Using ISO/IEC 20387	Cory Arant	United States
PA-03	How Qatar Biobank is Engaging Young Minds and Supporting Future Biobankers	Linda Hannigan	Qatar
PA-04	Successful Customer Satisfaction Indices as a Biobank Metric	Zachery von Menchhofen	United States
PA-05	A Robust Quality Management System is Essential for High-quality Tissue Acquisition in Biobanking	Aurora Mejia	Canada
PA-06	Evidence-Based Biobanking: Hit the Ground Running with NCI's Biospecimen Evidence-Based Practices	Kelly Engel	United States
PA-07	Evaluation of Collections for Automated Sample Handling and Storage in a Biobank with Diverse Sample Sets	Kathi Shea	United States
PA-08	Comparison of Spectrophotometric and Fluorometric Findings on DNA Isolated from Shefa Al Orman Biobank Blood Samples	Aisha Gamal	Egypt
PA-09	Cost Recovery at The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit Biobank	Phillis Babirye	Uganda
PA-10	Quality Management Framework of Biobank-Raising the Standards for Cancer Research	Archana Sharma	India
PA-11	Maintaining Manual Laboratory Skills in a World of Automation - The Qatar Biobank Perspective	Linda Hannigan	Qatar
PA-12	Utilizing Strategic Communications and Social Media to Drive Qatar Biobank's Public Recruitment	Mohammed Aldosari	Qatar
PA-13	Towards Virtual SSPA Biobank: New Functionalities Integrated and Tools Developed to Improve Communication with Stakeholders	Ana Sánchez-López	Spain
PA-14	Introducing Scientific and Student Communities to the World of Biobanks Through a Massive Open Online Course. The Experience of the Institut Pasteur.	Raquel Hurtado-Ortiz	France
PA-15	Quality Assurance Through Biobanking Standards	Tafadzwa Maranjisi	Zimbabwe
PA-16	To Examine Unapproached/ Refusal Metrics Against Self-Reported Ethnic Diversity of Participants of the McCain GU Biobank	Leda Weiss	Canada
PA-17	Prior-Knowledge Assessment of Biobank Science Among South African Health Sciences Postgraduate and Senior Medical Students: Integration of Knowledge in Instructional Design and Curriculum Planning	Mandile Thobela	South Africa
PA-18	Biorepositories and Risk Assessment: Incorporating a Novel Tool of Combining Risk Strategies. A Proactive Approach.	Dianne Peterson	United States
PB-01	BC COVID-19 Biobank Network; Critical Infrastructure to Support Provincial Research	Tamsin Tarling	Canada
PB-02	The Busselton Health Study Biobank	Jennie Hui	Australia
PB-04	Value of Biobank Non-Cancer Samples	Marwa Saady	Egypt
PB-05	Integration and Synergies of Scientific Core Facilities – a Place for Biobanking? The Westmead Experience	Karena Pryce	Australia
PB-06	A Biospecimen and Biomarker Program of the National Biobank of Korea: An Application to the Korea National Health and Nutrition Examination Survey	Jae-Pil Jeon	South Korea
PB-07	Biobank Mississippi – A Biobank Enriched For African Americans	Gouri Mahajan	United States
PB-08	The Aswan Heart Centre Biobank: A powerful resource for Precision Medicine in Cardiovascular Science and Practice.	Basma Shenouda	Egypt
PB-09	University of Mississippi Medical Center Biobank-Growing Biorepository For Collaborative Research	Gouri Mahajan	United States
PB-10	The Regional Prospective Observational Research in Tuberculosis (RePORT) Brazil Biorepository and its Role in Tuberculosis Research	Pedro Borba	Brazil



ID	Title	Presenter	Country
PB-11	Predict, Prevent, Reverse, Cure – The Benaroya Research Institute Biorepository	Megan Smithmyer	United States
PC-01	The Role and Challenges for Office of Bio-Resources Planning at the Cluster of Biological Resource Centers	Tae-Eun Jin	South Korea
PC-02	Biobank Networks in Korea	Kwang Hoon Cho	South Korea
PC-03	A Non-Traditional Approach to Biobanking: When a Non-Profit Meets a Large Pediatric Medical Center	Michael Pauciulo	United States
PC-04	Nuts and Bolts of a Cancer Moonshot Biobank for Precision Medicine	Lokesh Agrawal	United States
PC-05	MBRIO Project: Identification of Technical and Non Technical Needs to Implement Biobanking Practise for Health Research in Indonesia	Jajah fachiroh	Indonesia
PC-06	Qatar Biobank Connecting Nodes Building Networks in the Pursuit of Precision Health	Eleni Fthenou	Qatar
PC-07	One-Stop Shopping: Aligning Biobank and Clinical Laboratory Tissue Services to Optimize Quality, Efficiency and Investigator Experience	Alexis Pifer	United States
PC-08	Overview of Strategic Planning and Progress of Korea Biobank Project (KBP4.0)	Hye-Young Nam	South Korea
PC-09	Implementation and Continual Enhancement of a Biospecimen Information Management System at an Academic Medical Center	Julie Oetinger	United States
PD-01	The First Biobank Internship in Egypt: Focusing on Undergraduates' Hands-on Experience in LIMCs	Amr Ragab	Egypt
PD-02	Biorepository Capacity for Emerging Infectious Disease Outbreak Research	Megan Averill	United States
PD-03	Epicatechin Affects Sperm Cryocapacitation through Changes in the Levels of Reactive Oxygen Species	Eva Tvrda	Slovakia
PD-04	The STAMP Egg Collection at the NIST Biorepository	Jennifer Hoguet	United States
PD-05	Implementing the ISO 20387: the Animal Resource Bank Experience, Transition from the ISO 9001 to ISO 20387	Se-Hee Choe	South Korea
PD-06	Role of Reduced Glutathione in Extender for Liquid Storage of Ring-Necked Pheasant Semen	Bushra Rakha	Pakistan
PD-07	The MARS PETCARE BIOBANK: Establishing a Longitudinal Study of Health and Disease in Dogs and Cats	Janet Alexander	United Kingdom
PD-09	Sclerochronology Applications in Sea Turtle Scutes Sourced from Historical Archives	Kyle Van Houten	United States
PE-01	ONCOPassport Diagnostic Service for the Improvement of Lung Cancer Targeted Therapy	Anna Michalska-Falkowska	Poland
PE-03	Preliminary Study for SNP Array Analysis of DNA Derived from Blood Smears Stored for More Than 50 Years	Tomonori Hayashi	Japan
PE-04	Cost Assessment of Cryogenic Preservation of Biocollections During the COVID Pandemic at CeReB 2020-2021	Aka Edwige	Côte d'Ivoire
PE-05	Plasma miRNA Profile in High Risk of Preterm Birth during Early and Mid-Pregnancy	Roman Illarionov	Russian Federation
PE-06	The Mathison Centre Neurogenetics Biobank and Advancing in Precision Mental Health	S-M Shaheen	Canada
PE-07	Precision Medicine in Childhood Cancer: from Tiny Biospecimen to Big Possibilities!	Thomas Sontag	Canada
PE-08	Quality Analysis of Residual Genome DNA in Red Blood Cell Samples from Anticoagulated Whole Blood	Yuan Zhu	China
PE-10	Assessment of the Stability of Metabolic Parameters for Creation of Pre-Analytical Guidelines for Metabolomics	Alexander Funk	Germany
PE-11	Method Validation for PBMC Isolation and Cryopreservation: Old and New Preanalytical Variables	Raquel Hurtado-Ortiz	France
PE-12	Characterization of Process for Isolation of Peripheral Blood Mononuclear Cell (PBMC) using a Custom Layering Tool and a Custom Hourglass Tube	Danel Granda	United States
PE-14	Impact of Serum Indices on Serum Metabolite Profiles and its Association with Pre-Analytical Variables of Biobanked Samples	Juyoung Lee	South Korea
PE-15	Biobanking in the COVID-19 Times: Research on Serum Cytokine Profile and Tumor Biomarkers in Relation to Disease Severity Prognosis	Marie Karlikova	Czechia
PE-16	Long-Term Stability and Qualification of an Historical Fungal Collection	Adriana Chiarelli	France

ABRIDGED PROGRAM



PET In Supporting Diagnostic Research and Development with Biobanking Activities for Infectious Diseases Endemic Manne Librais Imane Librais Softward Control PET ID Incident PNA Quality Control Implementation in Oster Biobank Laboratories Morant Manne Jordan You Ontated States PET ID Incident PNA Quality Control Implementation in Oster Biobank Laboratories Jordan You United States PET ID Incident PNA Quality Control Implementation of Genomic DNA from Various Leftover Blood Samples Openand National Control United States PET ID Incidentified PNA Quality For mr PTET Save through Ullivasorication Sharehold National Control Moranted Kaushall United States PET ID Incidentified PNA Quality For mr PTET Save through Ullivasorication Sharehold National Writerhand Research United States PET ID Incidentified PNA Quality For mr PTET Save through Ullivasorication Child States Writerhand Research United States PET ID Incidentified PNA Quality For mr PTET Save through Ullivasorication of Character States in Provention of Manne Amenium Propendition For Research United States PET ID Incidentified PNA Quality Control (States) and Provention Tropestations on Recovery of Posterories Goal Skin Derived Fribrobles Coll Manne Amenium) United States PET ID Incidentified PNA Quality Control (States) Amenium Properties Cryptoprocessing on Processwill provention Goa	ID	Title	Presenter	Country
PETB Automatic and Robast Extraction of Genomic DNA from Various Leitover Blood Samples january You United States PE-20 A Case Study; Extending Downstream Applications for a Stabilized Withole Blood Collection Tube. Olga Kofanova Luxembourg PE-21 Discovery Through Biospecimen Sharing; The NASA Rollogical Institutional Scientific Collection (NBISC) Joseph Varietas United States PE-22 Enhancing RNA Quality from FPE Tissue through Ultrasonication Sharmeels Issued States The Peringhementation Qualification Study of Blood-Based Bloomarker Assay Precision to Establish Consistent and Kristen Russ United States PE-23 Roll-information Study of Blood-Based Bloomarker Assay Precision to Establish Consistent and Received Value of Received Precision to Establish Consistent and Received Value of Received Precision to Establish Consistent and Received Precision Received Precision to Establish Consistent Assay Precision to Establish Consistent and Received Precision Received Precision to Establish Consistent Precision Received Precision to Establish Consistent Precision Received Precision to Establish Consistent Precision Received Precis	PE-17		Imane El Idrissi	Switzerland
PF-202 A Cases Study: Extending Downstream Applications for a Stabilized Whole Blood Collection Tube. Olga Kofanova Luxemborder PE-21 Discovery Through Biospecimen Sharing: The NASA Biological Institutional Scientific Collection (NBISC) Joseph Varieties United States PE-22 Enhancing RNA Qualify from FFFE Tissue through Ultrasorication Sharmeelia Kaushal United States PE-23 Relabeloa Data Return Not Pre-Implementation Qualification Study of Blood-Based Biomarker Assay Precision to Establish Consistent and Kristen Russ Wristen Russ United States PE-24 A Multispectural Thurrecornec Lifetime Imaging (FLMI) System For Repid Biochemical Assessment Of Fresh And Vikrishnan Ramanujan United States PE-25 Role of Biospecimen Science in Cancer Biomarkers: A Funding Opportunity for Basic and Clinical Researchers Lokes h Agrawal United States PE-26 Rifect of Different Cryopresenation Temperatures on Recovery of Postmortem Goat Skin Derived Fibroblast Cell Makipal Singh United States PE-27 The Neode for Standardized Cryoprocessing on Preservation Outcomes Lukas Underwood United States PE-28 The Value of a Gift – Understanding the Perceived Value of Post-Mortem Brain Donation For Research Cassandra Griffin Australia PE-	PE-18	Functional DNA Quality Control Implementation in Qatar Biobank Laboratories	Nesrin Hacine	Qatar
PE-21 Discovery Through Biospecimen Sharing: The NASA Biological Institutional Scientific Collection (NBISC) Joseph Varielies United States PE-22 Enhancing RNA Qualify from FFPE Tissue through Ultrasonication Sharmeela Kaushal United States FE-23 Reliable Data Return The Implementation Qualification Study of Blood-Based Biomarker Assay Precision to Establish Consistent and Kristen Russ United States FE-24 AMUftspectral Fluorescence Ulterime Imaging (FUM) System For Rapid Biochemical Assessment Of Fresh And Protecting Insue Speciments in Blobank Settings United States FE-25 Role of Biospecimens Science in Cancer Biomarkers: A Funding Opportunity for Basic and Clinical Researchers Lokesh Agrawal United States FE-26 Effect of Different Cryopreservation Temperatures on Recovery of Postmortern Goat Skin Derived Flibroblast Call Wahipal Singh United States FE-27 The Value of a GRI – Understanding the Preceived Value of Post-Mortern Brain Donation For Research Cassandra Griffin Australia FE-28 Assessing the Quality of Plasma Obtained from Blood Plasma Separation Microdevice for Uquid Bloops Assayls Siddiqi India FE-29 Assessing the Quality of Plasma Obtained from Blooperimen Integrity Schupler Kremer Cassandra Griffin August National Blooperimen Activity in Clini	PE-19	Automatic and Robust Extraction of Genomic DNA from Various Leftover Blood Samples	Jianlan You	United States
PE-22 Enhancing RNA Quality from FFPE Trissus through Ultrasonication Sharmeeta Kaushal United States PE-23 Pre-Implementation Qualification Study of Blood-Based Biomarker Assay Precision to Establish Consistent and Reliable Data Return United States PE-24 Ambitapectral Fluorescence Uletime Imaging (FLIM) System For Rapid Biochemical Assessment Of Fresh And Frozen Tissue Specimens In Biochank Settings United States PE-25 Role of Biospecimen Science in Cancer Biomarkers: A Funding Opportunity for Basic and Clinical Researchers Lokesh Agrawal United States PE-26 Effect of Different Cryopreservation Temperatures on Recovery of Postmortem Gost Skin Derived Fibroblast Cell Mahipai Singh United States PE-27 The Need for Standardized Cryoprocessing on Preservation Outcomes Lukas Underwood United States PE-28 The Value of a Gift - Understanding the Perceived Value of Post-Mortem Brain Donation For Research Cassandra Griffin Australia PE-29 Assessing the Quality of Plasma Obtained from Blood Plasma Separation Microdevice for Liquid Biopsy Mayla Siddigl India PE-20 Assessing the Quality of Plasma Obtained from Blood Plasma Separation Microdevice for Liquid Biopsy Kenneth Chang Tour Fin Ele Thit PE-20 Assessing the Quality of Plasma Obtained from B	PE-20	A Case Study: Extending Downstream Applications for a Stabilized Whole Blood Collection Tube.	Olga Kofanova	Luxembourg
PF-232 Pre-Implementation Qualification Study of Blood-Based Blomarker Assay Precision to Establish Consistent and Reliable Data Return United States PE-24 A Multispectral Fluorescence Lifetime Imaging (FLIM) System For Rapid Blochemical Assessment Of Fresh And Amultispectral Fluorescence Lifetime Imaging (FLIM) System For Rapid Blochemical Assessment Of Fresh And Virisinan Ramanujan United States PE-25 Role of Biospecimen Science in Cancer Blomarkers: A Funding Opportunity for Basic and Clinical Researchers Lokesh Agrawal United States PE-26 Englished Englished Mahipal Singh United States PE-27 The Need for Standardized Cryoprocessing on Preservation Outcomes Lukas Underwood United States PE-28 The Value of a Gift - Understanding the Perceived Value of Post-Mortem Brain Donation For Research Cassandra Griffin Australia PE-29 Assessing the Quality of Plasma Obtained from Blood Plasma Separation Microdevice for Liquid Biosps Maayla Siddiciq India PE-30 Assessing the Quality of Plasma Obtained from Blood Plasma Separation Microdevice for Liquid Biosps Kenneth Chang Tou English Research Result India PE-30 Oversight of Tissue Banking Activity in Clinical Trials by Sing Health Tissue Repository Kenneth Chang Tou English Remember Chang Tou English <	PE-21	Discovery Through Biospecimen Sharing: The NASA Biological Institutional Scientific Collection (NBISC)	Joseph Varelas	United States
FEED Reliable Data Return Multipactural Fluorescence Lifetime Imaging (FLIM) System For Rapid Biochemical Assessment Of Fresh And A Multipacetral Fluorescences In Biochank Settings Viride States FEE24 A Multipacetral Fluorescence Lifetime Imaging (FLIM) System For Rapid Biochemical Assessment Of Fresh And Prozen Tissue Specimens In Biochank Settings United States FEE25 Role of Biospecimen Science in Cancer Biomarkers: A Funding Opportunity for Basic and Clinical Researchers Lokesh Agrawal United States FE26 Efflect of Different Cryopreservation Temperatures on Recovery of Postmorterm Goals Skin Derived Fibroblast Cell problems of Propulations Mahipal Singh United States FE27 The Need for Standardized Cryoprocessing on Preservation Outcomes Lukas Underwood United States FE28 The Value of a Gift – Understanding the Perceived Value of Post-Mortem Brain Donation For Research Cassandra Griffin Australia FE-20 Assessing the Quality of Plasma Obtained from Blood Plasma Separation Microdevice for Liquid Biopsy Application Mayayla Siddiogi Incide FE-21 Assessing the Quality of Plasma Obtained from Blood Plasma Separation Microdevice for Liquid Biopsy Applications and Separation Microdevice for Liquid Biopsy Applications Schulper Kremer United States FE-22 Assessing the Quality of Plasma Obtains and Separation Integ	PE-22	Enhancing RNA Quality from FFPE Tissue through Ultrasonication	Sharmeela Kaushal	United States
Fe24 Frozen Tissue Specimens In Biobank Settings Frozen Tissue Specimens In Biobank Settings Frozen Tissue Specimens Science in Cancer Biomarkers: A Funding Opportunity for Basic and Clinical Researchers Effect of Different Cryopreservation Temperatures on Recovery of Postmortem Goat Skin Derived Fibroblast Cell Mahipal Singh United States FE-27 The Need for Standardized Cryoprocessing on Preservation Outcomes Lukas Underwood United States FE-28 The Value of a Gilt – Understanding the Perceived Value of Post-Mortem Brain Donation For Research Eassaing the Quality of Plasma Obtained from Blood Plasma Separation Microdevice for Liquid Biopsy Assessing the Quality of Plasma Obtained from Blood Plasma Separation Microdevice for Liquid Biopsy Assessing the Quality of Plasma Obtained from Blood Plasma Separation Microdevice for Liquid Biopsy Assessing the Quality of Plasma Obtained from Blood Plasma Separation Microdevice for Liquid Biopsy Assessing the Quality of Plasma Obtained from Blood Plasma Separation Microdevice for Liquid Biopsy Assessing the Quality of Plasma Obtained from Blood Plasma Separation Microdevice for Liquid Biopsy Assessing the Quality of Plasma Obtained from Blood Plasma Separation Microdevice for Liquid Biopsy Assessing the Quality of Plasma Obtained From Blooder Plasma Separation Microdevice for Liquid Biopsy Assessing the Quality of Plasma Obtained From Blooder Plasma Separation Microdevice for Liquid Biopsy Economic Assessing Microder of Pediatric Biospecimen Integrity Schuyler Kremer United States Pr-04 Oversight of Tissue Banking Activity in Clinical Trials by SingHealth Tissue Repository Effect to Scale Return of Research Results in the Mayo Clinic Biobank Pr-04 Differences and Smith Media Plasma Separation Activity and Biobank Pr-04 Differences and Smith Media Plasma Separation Activated Biobank Pr-05 Biobank Specific Regulatory Requirements and How to Address Them Pr-06 Biobank Specific Regulatory Requirements and How to Address Them Pr-07 Biobank Specific R	PE-23		Kristen Russ	United States
PE-26 Effect of Different Cryopreservation Temperatures on Recovery of Postmortem Goat Skin Derived Fibroblast Cell Mahipal Singh United States PE-27 The Need for Standardized Cryoprocessing on Preservation Outcomes Lukas Underwood United States PE-28 The Vailue of a Gift – Understanding the Perceived Value of Post-Mortem Brain Donation For Research Cassandra Griffin Australia PE-29 Assessing the Quality of Plasma Obtained from Blood Plasma Separation Microdevice for Liquid Biopsy Application Maayla Siddiqi India PE-30 AS-Cys-Albumin As a Biomarker of Pediatric Biospecimen Integrity Schuyler Kremer United States PF-01 Oversight of Tissue Banking Activity in Clinical Trials by SingHealth Tissue Repository Kenneth Chang Tou En. Singapore PF-02 Incorporating Equity, Diversity, and Inclusion into a Canadian Biobank Tams in Tarling Canadian PF-03 Efforts to Scale Return of Research Results in the Mayo Clinic Biobank Nicole Larson United States PF-04 Advituding Requisition Model for Balanced Application of Ethical & Religious Directives, Federal Regulations, and Virtual Biobank Operations at CHRISTUS Virtual Biobanking Pulser Rati United States PF-06 A Successful Minority Outreach Model for Biobanking A Multi-	PE-24		V Krishnan Ramanujan	United States
FE2-20 Populations Manipal Singh United States PE-27 The Need for Standardized Cryoprocessing on Preservation Outcomes Lukas Underwood United States PE-28 The Value of a Gift – Understanding the Perceived Value of Post-Mortern Brain Donation For Research Cassandra Griffin Australia PE-29 Assessing the Quality of Plasma Obtained from Blood Plasma Separation Microdevice for Liquid Biopsy Application Maayla Siddiqi Inclia PF-30 AS-Cys-Albumin As a Biomarker of Pediatric Biospecimen Integrity Schuyler Kremer United States PF-01 Incorporating Equity, Diversity, and Inclusion into a Canadian Biobank Tamsin Tarling Canada PF-02 Incorporating Equity, Diversity, and Inclusion into a Canadian Biobank Nicole Larson United States PF-03 Efforts to Scale Return of Research Results in the Mayo Clinic Biobank Nicole Larson United States PF-04 AMulti-Prong Operating Model for Balanced Application of Ethical & Religious Directives, Federal Regulations, and Virtual Biobank Operations at C-HRISTUS Virtual Biobank Pulkar Ratti United States PF-05 Biobank-Specific Regulatory Requirements and How to Address Them Leda Weiss Canada PF-06 What Egyptians Think I Knowledge, Perceptions and Attitude of Egyptian Stakeholders towards Biobanking Ahmed Abdelhafiz Egypt	PE-25	Role of Biospecimen Science in Cancer Biomarkers: A Funding Opportunity for Basic and Clinical Researchers	Lokesh Agrawal	United States
PE-28 The Value of a Gift – Understanding the Perceived Value of Post-Mortem Brain Donation For Research Cassandra Griffin Australia PE-29 Assessing the Quality of Plasma Obtained from Blood Plasma Separation Microdevice for Liquid Biopsy Application Maayla Siddiqi India PE-30 AS-Cys-Albumin As a Biomarker of Pediatric Biospecimen Integrity Schuyler Kremer United States PF-01 Oversight of Tissue Banking Activity in Clinical Trials by SingHealth Tissue Repository Kenneth Chang Tou En. Eli Thit Singapore Eli Thit PF-02 Incorporating Equity, Diversity, and Inclusion into a Canadian Biobank Tamsin Tarling Canada PF-03 Efforts to Scale Return of Research Results in the Mayo Clinic Biobank Nicole Larson United States PF-04 AMulti-Prong Operating Model for Balanced Application of Ethical & Religious Directives, Federal Regulations, and Virtual Biobank Operations at CHRISTUS Virtual Biobank Pukar Ratti United States PF-04 A Successful Minority Outreach Model for Biobanking Sharmeela Kaushal United States PF-05 Biobank-Specific Regulatory Requirements and How to Address Them Leda Weiss Canada PF-06 Differences and Similarities Between Local and Global Genetic Information Law and Regulatory Consideration	PE-26		Mahipal Singh	United States
PE-29 Assessing the Quality of Plasma Obtained from Blood Plasma Separation Microdevice for Liquid Biopsy Application Maayla Siddiqi India PE-30 ▲S-Cys-Albumin As a Biomarker of Pediatric Biospecimen Integrity Schuyler Kremer United States PF-01 Oversight of Tissue Banking Activity in Clinical Trials by SingHealth Tissue Repository Kenneth Chang Tou En. Eli Thit Singapore PF-02 Incorporating Equity, Diversity, and Inclusion into a Canadian Biobank Tamsin Tarling Canada PF-03 Efforts to Scale Return of Research Results in the Mayo Clinic Biobank Nicole Larson United States PF-04 A Multi-Prong Operating Model for Balanced Application of Ethical & Religious Directives, Federal Regulations, and Virtual Biobank Operations at CHRISTUS Virtual Biobank and Propose and Similarities Between Local and Global Genetic Information Law and Regulatory Considerations Leda Weiss Canada PF-05 Biobank-Specific Regulatory Requirements and How to Address Them Leda Weiss Canada PF-06 Differences and Similarities Between Local and Global Genetic Information Law and Regulatory Considerations Leda Weiss Canada PF-07 What Egyptians Think! Knowled	PE-27	The Need for Standardized Cryoprocessing on Preservation Outcomes	Lukas Underwood	United States
Application Maayla Siddiq India PE-30 AS-Cys-Albumin As a Biomarker of Pediatric Biospecimen Integrity Schuyler Kremer United States PF-01 Oversight of Tissue Banking Activity in Clinical Trials by SingHealth Tissue Repository Kenneth Chang Tou En. FIET Thit Singapore FIF-02 Incorporating Equity, Diversity, and Inclusion into a Canadian Biobank Tamsin Tarling Canada FF-03 Efforts to Scale Return of Research Results in the Mayo Clinic Biobank Nicole Larson United States FF-04 AMUlti-Prong Operating Model for Balanced Application of Ethical & Religious Directives, Federal Regulations, and Virtual Biobank Operations at CHRISTUS Virtual Biobank FF-05 A Successful Minority Outreach Model for Biobanking Sharmeela Kaushal United States FF-06 A Successful Minority Outreach Model for Biobanking Sharmeela Kaushal United States FF-07 Biobank-Specific Regulatory Requirements and How to Address Them Leda Weiss Canada FF-08 Differences and Similarities Between Local and Global Genetic Information Law and Regulatory Considerations Leda Weiss Canada FF-09 What Egyptians Think! Knowledge, Perceptions and Attitude of Egyptian Stakeholders towards Biobanking Ahmed Abdellhafiz Egypt FF-10 Consent Tools for Pediatric Research Involving Databases and Biobanks FF-01 The Importance and the Specific Method of Education and Training in Biobanking Karine Sargsyan Austria FF-04 Pre and Post-COVID-19 Biospecimens Trend at Princess Margaret Cancer Biobank Aurora Mejia-Benitez Canada FF-05 The Medical Research Council/Uganda Virus Research Involving Databases of 2019 in Uganda FF-06 Harmonization of Electronic Medical Records Diagnoses Between Harnad Medical Corporation and Qatar Biobank FF-07 Biospecimen and Data Resources from the Cancer Moonshot Biobank FF-08 What Happens to Recruitment Rates at a Biobank when Healthcare Goes Virtual Health Care FF-08 What Happens to Recruitment Rates at a Biobank when Healthcare Goes Virtual Health Care FF-09 Rationale for a Hybridized Consent Workflow in a Biobank Adapting to Virtual Health Care FF-09 R	PE-28	The Value of a Gift – Understanding the Perceived Value of Post-Mortem Brain Donation For Research	Cassandra Griffin	Australia
PF-01 Oversight of Tissue Banking Activity in Clinical Trials by SingHealth Tissue Repository Ei Ei Thit PF-02 Incorporating Equity, Diversity, and Inclusion into a Canadian Biobank Tamsin Tarling Canada PF-03 Efforts to Scale Return of Research Results in the Mayo Clinic Biobank Nicole Larson United States PF-04 AMulti-Prong Operating Model for Balanced Application of Ethical & Religious Directives, Federal Regulations, and Virtual Biobank Operations at CHRISTUS Virtual Biobank PF-06 A Successful Minority Outreach Model for Biobanking Sharmeela Kaushal United States PF-07 Biobank-Specific Regulatory Requirements and How to Address Them Leda Weiss Canada PF-08 Differences and Similarities Between Local and Global Genetic Information Law and Regulatory Considerations Leda Weiss Canada PF-09 What Egyptians Thinkl Knowledge, Perceptions and Attitude of Egyptian Stakeholders towards Biobanking Ahmed Abdelhafiz Egypt PF-10 Consent Tools for Pediatric Research Involving Databases and Biobanks Dimitri Patrinos Canada PG-01 The Importance and the Specific Method of Education and Training in Biobanking Karine Sargsyan Austria PG-04 Pre and Post-COVID-19 Biospecimens Trend at Princess Margaret Cancer Biobank PG-05 The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit Biobank Experience and Continuation during Corona Virus Disease of 2019 in Uganda PG-06 Harmonization of Electronic Medical Records Diagnoses Between Hamad Medical Corporation and Qatar Biobank Kawthar Al-Dabhani Qatar PG-07 Biospecimen and Data Resources from the Cancer Moonshot Biobank PG-08 What Happens to Recruitment Rates at a Biobank when Healthcare Goes Virtual Health Care PG-08 Rationale for a Hybridized Consent Workflow in a Biobank Adapting to Virtual Health Care PG-09 Rationale for a Hybridized Consent Workflow in a Biobank Adapting to Virtual Health Care PG-09 Rationale for a Hybridized Consent Workflow in a Biobank Adapting to Virtual Health Care	PE-29		Maayla Siddiqi	India
PF-02 Incorporating Equity, Diversity, and Inclusion into a Canadian Biobank Tamsin Tarling Canada PF-03 Efforts to Scale Return of Research Results in the Mayo Clinic Biobank Nicole Larson United States PF-04 A Multi-Prong Operating Model for Balanced Application of Ethical & Religious Directives, Federal Regulations, and Virtual Biobank Operations at CHRISTUS Virtual Biobank PF-06 A Successful Minority Outreach Model for Biobanking Sharmeela Kaushal United States PF-07 Biobank-Specific Regulatory Requirements and How to Address Them Leda Weiss Canada PF-08 Differences and Similarities Between Local and Global Genetic Information Law and Regulatory Considerations Leda Weiss Canada PF-09 What Egyptians Think! Knowledge, Perceptions and Attitude of Egyptian Stakeholders towards Biobanking Ahmed Abdelhafiz Egypt PF-10 Consent Tools for Pediatric Research Involving Databases and Biobanks Dimitri Patrinos Canada PG-01 The Importance and the Specific Method of Education and Training in Biobanking Karine Sargsyan Austria PG-04 Pre and Post-COVID-19 Biospecimens Trend at Princess Margaret Cancer Biobank Aurora Mejia-Benitez Canada PG-05 The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine PG-06 Harmonization of Electronic Medical Records Diagnoses Between Harnad Medical Corporation and Qatar Biobank Kawthar Al-Dabhani Qatar PG-07 Biospecimen and Data Resources from the Cancer Moonshot Biobank PG-08 What Happens to Recruitment Rates at a Biobank when Healthcare Goes Virtual? PG-08 What Happens to Recruitment Rates at a Biobank when Healthcare Goes Virtual? PG-09 Rationale for a Hybridized Consent Workflow in a Biobank Adapting to Virtual Health Care Andrea Tyler Canada	PE-30	Δ S-Cys-Albumin As a Biomarker of Pediatric Biospecimen Integrity	Schuyler Kremer	United States
PF-03 Efforts to Scale Return of Research Results in the Mayo Clinic Biobank PF-04 A Multi-Prong Operating Model for Balanced Application of Ethical & Religious Directives, Federal Regulations and Virtual Biobank Operations at CHRISTUS Virtual Biobank PF-06 A Successful Minority Outreach Model for Biobanking PF-07 Biobank-Specific Regulatory Requirements and How to Address Them PF-08 Differences and Similarities Between Local and Global Genetic Information Law and Regulatory Considerations PF-09 What Egyptians Think! Knowledge, Perceptions and Attitude of Egyptian Stakeholders towards Biobanking PF-10 Consent Tools for Pediatric Research Involving Databases and Biobanks PF-01 The Importance and the Specific Method of Education and Training in Biobanking PF-02 Pre and Post-COVID-19 Biospecimens Trend at Princess Margaret Cancer Biobank PG-03 The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine PG-05 The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine PG-06 Harmonization of Electronic Medical Records Diagnoses Between Hamad Medical Corporation and Qatar Biobank PG-07 Biospecimen and Data Resources from the Cancer Moonshot Biobank PG-08 What Happens to Recruitment Rates at a Biobank when Healthcare Goes Virtual? PG-08 Rationale for a Hybridized Consent Workflow in a Biobank Adapting to Virtual Health Care PG-09 Rationale for a Hybridized Consent Workflow in a Biobank Adapting to Virtual Health Care PG-00 Andrea Tyler PG-01 Rationale for a Hybridized Consent Workflow in a Biobank Adapting to Virtual Health Care PG-01 Rationale for a Hybridized Consent Workflow in a Biobank Adapting to Virtual Health Care PG-06 Andrea Tyler PG-07 Canada PG-07 Rationale for a Hybridized Consent Workflow in a Biobank Adapting to Virtual Health Care PG-07 Rational PG-07 Andrea Tyler PG-08 Rationale for a Hybridized Consent Workflow in a Biobank Adapting to Virtual Health Care PG-08 Rationale for a Hybridized Consent Workfl	PF-01	Oversight of Tissue Banking Activity in Clinical Trials by SingHealth Tissue Repository		Singapore
A Multi-Prong Operating Model for Balanced Application of Ethical & Religious Directives, Federal Regulations, and Virtual Biobank Operations at CHRISTUS Virtual Biobank PF-06 A Successful Minority Outreach Model for Biobanking PF-07 Biobank-Specific Regulatory Requirements and How to Address Them Leda Weiss Canada PF-08 Differences and Similarities Between Local and Global Genetic Information Law and Regulatory Considerations Leda Weiss Canada PF-09 What Egyptians Think! Knowledge, Perceptions and Attitude of Egyptian Stakeholders towards Biobanking Ahmed Abdelhafiz Egypt PF-10 Consent Tools for Pediatric Research Involving Databases and Biobanks Dimitri Patrinos Canada PG-01 The Importance and the Specific Method of Education and Training in Biobanking Karine Sargsyan Austria PG-04 Pre and Post-COVID-19 Biospecimens Trend at Princess Margaret Cancer Biobank PG-05 The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit Biobank Experience and Continuation during Corona Virus Disease of 2019 in Uganda PG-06 Harmonization of Electronic Medical Records Diagnoses Between Hamad Medical Corporation and Qatar Biobank PG-07 Biospecimen and Data Resources from the Cancer Moonshot Biobank PG-08 What Happens to Recruitment Rates at a Biobank when Healthcare Goes Virtual Health Care Andrea Tyler Canada PG-09 Rationale for a Hybridized Consent Workflow in a Biobank Adapting to Virtual Health Care Andrea Tyler Canada	PF-02	Incorporating Equity, Diversity, and Inclusion into a Canadian Biobank	Tamsin Tarling	Canada
PF-06 A Successful Minority Outreach Model for Biobanking Sharmeela Kaushal United States PF-07 Biobank-Specific Regulatory Requirements and How to Address Them Leda Weiss Canada PF-08 Differences and Similarities Between Local and Global Genetic Information Law and Regulatory Considerations Leda Weiss Canada PF-09 What Egyptians Thinkl Knowledge, Perceptions and Attitude of Egyptian Stakeholders towards Biobanking Ahmed Abdelhafiz Egypt PF-10 Consent Tools for Pediatric Research Involving Databases and Biobanks Dimitri Patrinos Canada PG-01 The Importance and the Specific Method of Education and Training in Biobanking Karine Sargsyan Austria PG-04 Pre and Post-COVID-19 Biospecimens Trend at Princess Margaret Cancer Biobank Aurora Mejia-Benitez Canada PG-05 The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit Biobank Experience and Continuation during Corona Virus Disease of 2019 in Uganda PG-06 Harmonization of Electronic Medical Records Diagnoses Between Harnad Medical Corporation and Qatar Biobank Rawhar Al-Dabhani Qatar PG-07 Biospecimen and Data Resources from the Cancer Moonshot Biobank PG-08 What Happens to Recruitment Rates at a Biobank when Healthcare Goes Virtual? PG-09 Rationale for a Hybridized Consent Workflow in a Biobank Adapting to Virtual Health Care Andrea Tyler Canada	PF-03	Efforts to Scale Return of Research Results in the Mayo Clinic Biobank	Nicole Larson	United States
PF-07 Biobank-Specific Regulatory Requirements and How to Address Them PF-08 Differences and Similarities Between Local and Global Genetic Information Law and Regulatory Considerations PF-09 What Egyptians Think! Knowledge, Perceptions and Attitude of Egyptian Stakeholders towards Biobanking PF-10 Consent Tools for Pediatric Research Involving Databases and Biobanks PG-01 The Importance and the Specific Method of Education and Training in Biobanking PG-04 Pre and Post-COVID-19 Biospecimens Trend at Princess Margaret Cancer Biobank PG-05 The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit Biobank Experience and Continuation during Corona Virus Disease of 2019 in Uganda PG-06 Harmonization of Electronic Medical Records Diagnoses Between Hamad Medical Corporation and Qatar Biobank PG-07 Biospecimen and Data Resources from the Cancer Moonshot Biobank PG-08 What Happens to Recruitment Rates at a Biobank when Healthcare Goes Virtual Pealth Care PG-08 Rationale for a Hybridized Consent Workflow in a Biobank Adapting to Virtual Health Care Andrea Tyler Canada	PF-04	A Multi-Prong Operating Model for Balanced Application of Ethical & Religious Directives, Federal Regulations, and Virtual Biobank Operations at CHRISTUS Virtual Biobank	Pukar Ratti	United States
PF-08 Differences and Similarities Between Local and Global Genetic Information Law and Regulatory Considerations Leda Weiss Canada PF-09 What Egyptians Think! Knowledge, Perceptions and Attitude of Egyptian Stakeholders towards Biobanking Ahmed Abdelhafiz Egypt PF-10 Consent Tools for Pediatric Research Involving Databases and Biobanks Dimitri Patrinos Canada PG-01 The Importance and the Specific Method of Education and Training in Biobanking Karine Sargsyan Austria PG-04 Pre and Post-COVID-19 Biospecimens Trend at Princess Margaret Cancer Biobank Aurora Mejia-Benitez Canada PG-05 The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit Biobank Experience and Continuation during Corona Virus Disease of 2019 in Uganda PG-06 Harmonization of Electronic Medical Records Diagnoses Between Hamad Medical Corporation and Qatar Biobank Kawthar Al-Dabhani Qatar PG-07 Biospecimen and Data Resources from the Cancer Moonshot Biobank PG-08 What Happens to Recruitment Rates at a Biobank when Healthcare Goes Virtual Pealth Care PG-09 Rationale for a Hybridized Consent Workflow in a Biobank Adapting to Virtual Health Care Andrea Tyler Canada	PF-06	A Successful Minority Outreach Model for Biobanking	Sharmeela Kaushal	United States
PF-09 What Egyptians Think! Knowledge, Perceptions and Attitude of Egyptian Stakeholders towards Biobanking Ahmed Abdelhafiz Egypt PF-10 Consent Tools for Pediatric Research Involving Databases and Biobanks Dimitri Patrinos Canada PG-01 The Importance and the Specific Method of Education and Training in Biobanking Karine Sargsyan Austria PG-04 Pre and Post-COVID-19 Biospecimens Trend at Princess Margaret Cancer Biobank Aurora Mejia-Benitez Canada PG-05 The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit Biobank Experience and Continuation during Corona Virus Disease of 2019 in Uganda PG-06 Harmonization of Electronic Medical Records Diagnoses Between Hamad Medical Corporation and Qatar Biobank Kawthar Al-Dabhani Qatar PG-07 Biospecimen and Data Resources from the Cancer Moonshot Biobank PG-08 What Happens to Recruitment Rates at a Biobank when Healthcare Goes Virtual? PG-09 Rationale for a Hybridized Consent Workflow in a Biobank Adapting to Virtual Health Care PG-10 Rationale for a Hybridized Consent Workflow in a Biobank Adapting to Virtual Health Care PG-09 What Happens to Recruitment Rates at a Biobank Adapting to Virtual Health Care PG-10 Rationale for a Hybridized Consent Workflow in a Biobank Adapting to Virtual Health Care	PF-07	Biobank-Specific Regulatory Requirements and How to Address Them	Leda Weiss	Canada
PF-10 Consent Tools for Pediatric Research Involving Databases and Biobanks Dimitri Patrinos Canada PG-01 The Importance and the Specific Method of Education and Training in Biobanking Karine Sargsyan Austria PG-04 Pre and Post-COVID-19 Biospecimens Trend at Princess Margaret Cancer Biobank PG-05 The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit Biobank Experience and Continuation during Corona Virus Disease of 2019 in Uganda PG-06 Harmonization of Electronic Medical Records Diagnoses Between Hamad Medical Corporation and Qatar Biobank PG-07 Biospecimen and Data Resources from the Cancer Moonshot Biobank PG-08 What Happens to Recruitment Rates at a Biobank when Healthcare Goes Virtual? PG-09 Rationale for a Hybridized Consent Workflow in a Biobank Adapting to Virtual Health Care Andrea Tyler Canada	PF-08	Differences and Similarities Between Local and Global Genetic Information Law and Regulatory Considerations	Leda Weiss	Canada
PG-01 The Importance and the Specific Method of Education and Training in Biobanking Karine Sargsyan Austria PG-04 Pre and Post-COVID-19 Biospecimens Trend at Princess Margaret Cancer Biobank Aurora Mejia-Benitez Canada PG-05 The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit Biobank Experience and Continuation during Corona Virus Disease of 2019 in Uganda PG-06 Harmonization of Electronic Medical Records Diagnoses Between Hamad Medical Corporation and Qatar Biobank Kawthar Al-Dabhani Qatar PG-07 Biospecimen and Data Resources from the Cancer Moonshot Biobank PG-08 What Happens to Recruitment Rates at a Biobank when Healthcare Goes Virtual? PG-09 Rationale for a Hybridized Consent Workflow in a Biobank Adapting to Virtual Health Care Andrea Tyler Canada	PF-09	What Egyptians Think! Knowledge, Perceptions and Attitude of Egyptian Stakeholders towards Biobanking	Ahmed Abdelhafiz	Egypt
PG-04 Pre and Post-COVID-19 Biospecimens Trend at Princess Margaret Cancer Biobank Aurora Mejia-Benitez Canada PG-05 The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit Biobank Experience and Continuation during Corona Virus Disease of 2019 in Uganda PG-06 Harmonization of Electronic Medical Records Diagnoses Between Hamad Medical Corporation and Qatar Biobank Kawthar Al-Dabhani Qatar Biospecimen and Data Resources from the Cancer Moonshot Biobank Ping Guan United States PG-08 What Happens to Recruitment Rates at a Biobank when Healthcare Goes Virtual? Leda Weiss Canada PG-10 Rationale for a Hybridized Consent Workflow in a Biobank Adapting to Virtual Health Care Andrea Tyler Canada	PF-10	Consent Tools for Pediatric Research Involving Databases and Biobanks	Dimitri Patrinos	Canada
PG-05 The Medical Research Council/Uganda Virus Research Institute and London School of Hygiene & Tropical Medicine Uganda Research Unit Biobank Experience and Continuation during Corona Virus Disease of 2019 in Uganda PG-06 Harmonization of Electronic Medical Records Diagnoses Between Hamad Medical Corporation and Qatar Biobank Kawthar Al-Dabhani Qatar Biospecimen and Data Resources from the Cancer Moonshot Biobank Ping Guan United States PG-08 What Happens to Recruitment Rates at a Biobank when Healthcare Goes Virtual? Leda Weiss Canada PG-10 Rationale for a Hybridized Consent Workflow in a Biobank Adapting to Virtual Health Care Andrea Tyler Canada	PG-01	The Importance and the Specific Method of Education and Training in Biobanking	Karine Sargsyan	Austria
Uganda Research Unit Biobank Experience and Continuation during Corona Virus Disease of 2019 in Uganda PG-06 Harmonization of Electronic Medical Records Diagnoses Between Hamad Medical Corporation and Qatar Biobank Kawthar Al-Dabhani Qatar PG-07 Biospecimen and Data Resources from the Cancer Moonshot Biobank Ping Guan United States PG-08 What Happens to Recruitment Rates at a Biobank when Healthcare Goes Virtual? Leda Weiss Canada PG-10 Rationale for a Hybridized Consent Workflow in a Biobank Adapting to Virtual Health Care Andrea Tyler Canada	PG-04	Pre and Post-COVID-19 Biospecimens Trend at Princess Margaret Cancer Biobank	Aurora Mejia-Benitez	Canada
PG-07 Biospecimen and Data Resources from the Cancer Moonshot Biobank Ping Guan United States PG-08 What Happens to Recruitment Rates at a Biobank when Healthcare Goes Virtual? Leda Weiss Canada PG-10 Rationale for a Hybridized Consent Workflow in a Biobank Adapting to Virtual Health Care Andrea Tyler Canada	PG-05		Phillis Babirye	Uganda
PG-08 What Happens to Recruitment Rates at a Biobank when Healthcare Goes Virtual? Leda Weiss Canada PG-10 Rationale for a Hybridized Consent Workflow in a Biobank Adapting to Virtual Health Care Andrea Tyler Canada	PG-06	Harmonization of Electronic Medical Records Diagnoses Between Hamad Medical Corporation and Qatar Biobank	Kawthar Al-Dabhani	Qatar
PG-10 Rationale for a Hybridized Consent Workflow in a Biobank Adapting to Virtual Health Care Andrea Tyler Canada	PG-07	Biospecimen and Data Resources from the Cancer Moonshot Biobank	Ping Guan	United States
	PG-08	What Happens to Recruitment Rates at a Biobank when Healthcare Goes Virtual?	Leda Weiss	Canada
PG-11 Refining Approach Strategies Using Pre- and Post-Covid Consent Metrics at the McCain GU Biobank Leda Weiss Canada	PG-10	Rationale for a Hybridized Consent Workflow in a Biobank Adapting to Virtual Health Care	Andrea Tyler	Canada
	PG-11	Refining Approach Strategies Using Pre- and Post-Covid Consent Metrics at the McCain GU Biobank	Leda Weiss	Canada



ID	Title	Presenter	Country
PG-12	Lessons Learned from the COVID-19 Pandemic: The Need for Flexible Biobanking of Healthy Control Samples	Leda Weiss	Canada
PG-13	Whole Community Living Microbiome Biobanking	Darya Chernikhova	Iceland
PH-01	Synergizing Biobanking Processes Between Academia And Commercial Biobanks.	Chon Boon Eng	Singapore
PH-02	Biobanking in East and Central Africa: A Case of the Integrated Biorepository of H3Africa Uganda	Gideon Nsubuga	Uganda
PH-03	Audit of Biospecimens at Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Biobank in Uganda	Esther Nabanoba	Uganda
PH-04	Overview of Shefa Al Orman Hospital Biobank in Upper Egypt	Rehab Mohamed	Egypt
PH-05	An Experience of Organizing and Maintaining the First National Tumour Tissue Repository (NTTR) in India	Sangeeta Desai	India
PH-06	To Keep or Not to Keep – Minimizing Biohoarding in a Resource Limited Setting.	juhi tayal	India
PH-07	Recruitment Strategies for a Non-Hospital Based Academic Biobank in South Africa: the Journey of the CHM Biobank	Engela Conradie	South Africa
PH-08	Evaluating the Efficacy of Density Gradient Centrifugation for the Biobanking of Malignant Cells in Patients with Hematological Disorders	Olga Bigun	Canada
PH-09	Ensuring Sustainability for Clinical Laboratory Support of Biospecimen Procurement	Megan Griffin	United States
PH-10	Van Andel Institute's Biospecimen Core Resource for the NCI Cancer Moonshot Biobank	Scott Jewell	United States
PH-11	Rapid Establishment of a Biospecimen Resource to Study the Global Impact of Covid-19 Vaccines	Karen Berliner	United States
PH-12	Translational-ANZGOG (TR-ANZGOG): Enhancing Translational Research Capacity in Gynaecological Cancer Clinical Trials to Optimize Research Impact	Claire Davies	Australia
PH-13	Effective Biobanking of Tissue Biopsies through Vaccum Sealing Method	Sindhu Govindan	India
PH-14	Cancer Screening and Biobanking: Insights from Community Wellness Initiative in India	Ruma Pengal	India
PH-15	Biobank at Indus Hospital & Health Network, Pakistan	Hanya Hussein Mohamed	Pakistan
PI-01	Implementing Natural Language Processing Technology in the Department of Pathology and Biorepository Using the eLearning for Staff Training	Galina Khramtsova	United States
PI-02	Application of Natural Language Processing in the Current and Future Work in the Department of Pathology and Institutional Biorepository	Galina Khramtsova	United States
PI-03	SIMBIOX, an In-House Data Management System for Biobanks in Indonesia	Ery Dwianingsih	Indonesia
PI-04	pccm_db: A Sophisticated High Granularity Breast Disease Dataset Created Utilizing a Easily Implementable Data Entry Too	Devaki Kelkar	India
PI-06	A Review of COVID-19 Lockdown Across Different Countries During 2020: Characterization of Risk Factors and Severity of COVID-19 in Egyptian Patients	Hanya Sayed	Egypt
PI-05	Data Profiling of HuBIS_Sam SPREC data of the Korea Biobank Network	Byeong Mun Heo	South Korea
PJ-01	Investigating the Labeling Workflow and Incorporation of Automation for Increased Collaborations	Amy Armstrong	United States
PJ-02	An Analytical Method to Determine Quality of Fixation Using Vibrational Spectroscopy and Machine Learning	David Chafin	United States
PJ-03	Sensitive Internal Thermal Monitoring Provides an Indication of Tank Health and Advance Alert for Impending Tank Failure	Michael Rusnack	United States
PJ-04	A New Cohort Study Management Application: Improvements to Efficiency and Morale in the Two Months Following Adoption	Rose Martin	United States
PJ-05	Fully Automated, Non-Destructive Processing and Imaging of Intact Tissue Samples	Michael Levene	United States
PJ-06	Justifying an Automated Biobank in Your Business Plan	Cory Tiller	United States

ABRIDGED PROGRAM



ID	Title	Presenter	Country
PK-01	Brain Tumor Biobanking in the Postmortem Setting	Katy McCortney	United States
PK-02	Implementing Technology to Enhance Sample Quality and Expedite Workflows at the National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)	Michael Edler	United States
PK-03	Increased Requests for Fresh Samples Impact the Workflow for The Cooperative Human Tissue Network (CHTN) Midwestern Division.	Randal Mandt	United States
PK-04	A Robust, Inexpensive Solution for Alarm Monitoring of Freezers, Incubators, and Other Biobank Equipment Based on Readily Available, Easy to Deploy Home Alarm Equipment	Jonathan Katz	United States
PK-05	Satellite Lab Concept to Reduce Processing Turnaround Time	Gary Welch	United States
PK-06	An Inside Look into Biobank Sustainability at UHN Biospecimen Services	Aurora Mejia	Canada
PK-07	$\label{thm:control} The \ Utilization \ of \ Sample \ Confirmation \ Testing \ (SCT) \ in \ Improving \ Quality \ Assurance \ and \ Quality \ Control \ in \ the \ eye GENE \ Biorepository$	Ranya Al Rawi	United States
PK-08	Communication with Participants: From the Report of the 3rd Biobank Open Forum "Biobank and Participation" Held in Japan	Junko Ikeda	Japan
PK-09	Fuelling Local Cancer Research by Establishing Biorepository Best Practices for Quality Samples at the University of Texas at El Paso	Shonali Paul	United States
PK-10	Evacuation of the Cryobank During of Military Aggression	Maryna Petrushko	Ukraine
PK-11	Risk Management of Total Inventory and Operations Transfer to a New Biobanking Space: A Case Study	Razan Humeida	United States
PK-12	Data Management Pipeline Implementation as a Tool to Foster 3.0 Biobanking	Teresa Botta	Spain
PK-13	Alessandria Biobank. Creation of Breast Cancer Collection	Giulia Oliveri	Italy
PK-14	Utilization of Study Specific Workflows in Conjunction with Standard Operating Procedures and/or Study Specific Laboratory Manuals to Manage Multiple Studies in a GCLP Biorepository	Robyn Osborne	United States
PK-15	Intraoperative Collection of Neurosurgical Biorepository Tissue	Beth Hermes	United States
PK-16	A Collaborative Communication Model to Support Quality Culture	Annemieke De Wilde	Belgium
PK-17	A Ten-Year Review of a Prospective Procurement Biospecimen IRB and the Influence on Specimen Procurement and Distribution at the Cooperative Human Tissue Network (CHTN) Midwestern Division.	Shelly Belcher	United States
PK-18	The Development and Implementation of an Overhauled Biospecimen Collection Database Within a Mature Biobank	Leda Weiss	Canada
PK-19	Moving the Duke Human Vaccine Institute (DHVI) Accessioning Unit and Biorepository During the COVID-19 Pandemic	Thaddeus Gurley	United States
PK-20	Metamorphosis in an Online Era: Migration of Consent Collections to a Paperless System by Digitization of Information	Aurora Mejia	Canada
PK-21	Exhuming Forgotten Treasures: Digitizing Archived Samples for the Future Generation	Aurora Mejia	Canada
PK-22	Building a Better Biorepository, Block by Block	Kristina Peterman	United States
PK-24	Use of The College of American Pathologists Competency Assessment Program to Maintain and Document Staff Training	Angela Butler	United States
PL-01	Qatar Biobank's (QBB) Journey for ISO 20387:2018 Accreditation	Wilma Lobo	Qatar
PL-02	High Quality BioBanking in Belgium: the Road towards ISO20387 Accreditation (B3-ISO)	Annemieke De Wilde	Belgium
PL-03	Biorepository Processing Data Standards and Data Validation As an indicator of Standard Operating Procedure Compliance and Biospecimen Quality	MaryBeth Joshi	United States
PL-04	The National Institute of Diabetes and Digestive and Kidney Diseases Central Repository Resources for Research (NIDDK-CR R4R): Enabling FAIRness and TRUSTworthiness with Data & Specimen Standards	Michael Keller	United States



Where biobanking is a mindset

And breakthroughs are born

Like you, the scientists at Thermo Fisher Scientific see things differently. We are dedicated to helping you realize your vision and change lives.

Our cutting-edge portfolio of biobanking products and services can support every stage of your workflow, giving you the power to secure and preserve samples, track inventory, streamline productivity, and meet your toughest laboratory challenges on the way to discovering your next breakthrough.



INTERNATIONAL SOCIETY FOR BIOLOGICAL AND ENVIRONMENTAL REPOSITORIES

Connect Globally to Leading Professionals in Biobanking

ISBER's vision is to be the leading network in the global biobanking and biorepository community.

ISBER advances the expertise and quality of biorepositories and biobanking science worldwide.



BENEFITS OF MEMBERSHIP INCLUDE:

- Free access to the ISBER *Best Practices for Repositories* and ISBER Biobank Assessment Tool (BAT)
- Opportunity to connect with a global network of professionals in biobanking through the ISBER Members-only Forum
- Access to Biopreservation and Biobanking (BIO), ISBER's official journal
- Reduced registration rates to ISBER meetings

NEW ISBER MEMBERS RECEIVE 15% OFF THEIR FIRST-YEAR OF MEMBERSHIP! READY TO JOIN? VISIT ISBER.ORG!



ISBER AND ASCP BOC ARE PLEASED TO ANNOUNCE THE QUALIFICATION IN REPOSITORY SCIENCE (QBRS) FOR BIOBANKERS.

Upon meeting specific educational and experience requirements for the qualification, candidates will be eligible to complete an online examination and, if successful, gain recognition for their skills and competencies as biobankers.

This new qualification will further advance the field of biorepository science! Biobanks are vital to medical research and precision medicine and require qualified professionals to obtain high quality results that will be useful in advancing biomedicine.

Earn *your*

QUALIFICATION IN BIOREPOSITORY SCIENCE
For biobanking professionals

ısber



NEW ROUTES AVAILABLE

Wondering if you can apply? Visit isber.org/qualification for details!

ONLINE COURSE:

ESSENTIALS OF BIOBANKING



- This online course provides learners with updated education on the key elements involved in planning, establishing, maintaining, and accessing a successful biobank
- Available in English and French





ISBER MEMBERS PRICE: \$195usd

Visit www.isber.org/EssentialsBiobanking



ISBER would like to thank the many individuals who have volunteered for the ISBER Best Practices, 5th Edition!

Editor-in-Chief

Emma Snapes

Best Practice Steering Committee

Annemieke De Wilde (Chair)
Jane Carpenter
Brent Schacter
Daniel Simeon-Dubach
Emma Snapes
Tamsin Tarling

Gap Analysis Task Force

Clare Allocca (Co-Chair)
Emma Snapes (Co-Chair)
Cory Arant
Marianna Bledsoe
Annemieke De Wilde
Sheila O'Donoghue
Elisabeth Standard
Peter Watson

Associate Editors

Jonas Astrin (Special Advisor) Gregory Grossman (Section Leader) Nina Bertheussen Krüger (Section Leader) Ellen Hendrickson (Section Leader) Nicola Miller (Section Leader) Cathy Seiler (Section Leader)

Contributors

Ahmed Samir Abdelhafiz
Rocio Aguilar Quesada
Christopher Battiston
Marianna Bledsoe
Marta Castelhano
Dianne Chadwick
Nilay Chakraborty
Michael Edler
Helena Ellis
Sarah Furlong
Nicola Gabancho
Debra Leiolani Garcia

Jason Acker Clare Allocca Fay Betsou Jennifer Byrne Lyn Healy
Marianne Henderson
Samantha Higgins
Paulo Holanda
Charles Hunt
Raquel Hurtado-Ortiz
Eric James
Peter Kilbride
Manisha Kulkarni
Carl Lessard
Kirsty Lloyd
Mantombi Maseme

Anna Michalska-Falkowska
Cheryl Michels
Amanda Moors
Hellen Nansumba
Trinh Nguyen
Adelina Ovcharenko
Shonali Paul
Jae Pil Jeon
lan Pope
Rebecca Pugh
Dean Rainbolt
Nilsa Ramirez

Billy Schlief
Ole Seberg
Purnima Singh
Glyn Stacey
Tatsuaki Tsuruyama
Rose Upton
Rainer Vollmer
Craig Willers
Erik Woods
Andy Zaayenga

Reviewers

Dan Catchpoole Jennifer Cvitanovic Annemieke de Wilde Koh Furuta Cassandra Griffin Kim Labuschagne David Levandowski Ellen Nordgren Brent Schacter Weiping Shao Tamsin Tarling Peter Watson





Incorporate the Biobank Assessment Tool into Your Quality Management System

Complimentary access for ISBER members

The ISBER Biobank Assessment Tool (BAT) assists repositories in evaluating how well their repository follows ISBER's Best Practices including the Cryo Addendum, and on a higher level also the ISO 20387 biobanking standard.

The BAT questionnaire consists of close to 200 questions corresponding to many areas of biobanking, such as repository planning, storage, and general quality management. The BAT can be used repeatedly, which

allows follow up every year, giving it a natural place in any quality management system (QMS), where implementation and follow-up of quantitative indicators are required.

To access the tool, please visit: www.isber.org/bat







The Champion of Efficiency

The best just got better.



PHC Corporation of North America is a subsidiary of PHC Holdings Corporation, Tokyo, Japan, a global leader in development, design and manufacturing of laboratory equipment for biopharmaceutical, life sciences, academic, healthcare and government markets.

LEARN MORE



PHC Corporation of North America

1300 Michael Drive, Suite A, Wood Dale, IL 60191 Toll Free USA (800) 858-8442, Fax (630) 238-0074 www.phchd.com/us/biomedical

Life Science Innovator Since 1966







ISOET REGIONAL MEETING **GRANADA, SPAIN**October 24-25, 2023

